Literature DB >> 3208790

Isolation and characterization of the urinary metabolites of arbaprostil in the male dog after intravenous administration.

B A Thornburgh1, S R Shaw, G E Bronson, A J Sinha.   

Abstract

The profile of urinary metabolites of 3H-arbaprostil was characterized in the male dog after intravenous administration. The major metabolites were purified and their structures deduced by gas chromatography/mass spectrometry (GC/MS) studies after conversion to the methyl ester-methoxime-trimethylsilyl ether derivatives, aided by GC with simultaneous radioactivity monitoring. The identified metabolites accounted for 96% of the urinary excretion products. beta-Oxidation of the carboxy side-chain of arbaprostil to 15-methyl-2,3,4,5-tetranor PGE1, via the 15-methyl-2,3-dinor PGE2 intermediate, appeared to be the most significant metabolic pathway. In contrast to the rat, the following were observed in the dog: glucuronic acid conjugation of the 15-methyl-2,3,4,5-tetranor PGE, and PGA metabolites; detection of the 15-methyl-2,3-dinor PGE2 intermediate; absence of 19-hydroxyl-15-methyl-2,3,4,5-tetranor PGA, and PGB metabolites; oxidation at C-20; and excretion of some parent drug.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3208790     DOI: 10.1007/BF03191312

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  9 in total

1.  The effect of 15(R)-15-methyl prostaglandin E2 on meal-stimulated gastric acid secretion, serum gastrin, and pancreatic polypeptide in duodenal ulcer patients.

Authors:  W Peterson; M Feldman; I Taylor; M Bremer
Journal:  Dig Dis Sci       Date:  1979-05       Impact factor: 3.199

Review 2.  Gastric antisecretory and antiulcer properties of PGE2, 15-methyl PGE2, and 16, 16-dimethyl PGE2. Intravenous, oral and intrajejunal administration.

Authors:  A Robert; J R Schultz; J E Nezamis; C Lancaster
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

3.  Comparison of methylated prostaglandin E2 analogues given orally in the inhibition of gastric responses to pentagastrin and peptone meal in man.

Authors:  S J Konturek; N Kwiecień; J Swierczek; J Oleksy; E Sito; A Robert
Journal:  Gastroenterology       Date:  1976-05       Impact factor: 22.682

4.  Effect of 15(R)-15-methyl prostaglandin E2 (arbaprostil) on the healing of duodenal ulcer: a double-blind multicenter study.

Authors:  G Vantrappen; J Janssens; T Popiela; J Kulig; G N Tytgat; K Huibregtse; R Lambert; J P Pauchard; A Robert
Journal:  Gastroenterology       Date:  1982-08       Impact factor: 22.682

5.  Absorption, tissue distribution, and excretion of 3H-labeled arbaprostil in the male rat.

Authors:  A J Sinha; S R Shaw; B A Thornburgh
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Apr-Jun       Impact factor: 2.441

6.  The inhibitory effect of 15(R)15 methyl prostaglandin E2 and the interaction with atropine on stimulated gastric acid secretion in man.

Authors:  B Kollberg; C Johansson
Journal:  Scand J Gastroenterol       Date:  1979       Impact factor: 2.423

7.  Dose response inhibition in man of meal-stimulated gastric acid secretion by 15(R)-15-methyl prostaglandin E2, given orally.

Authors:  A Robert; G Kane; S B Reele
Journal:  Gut       Date:  1981-09       Impact factor: 23.059

8.  Gastrointestinal protection by low-dose oral prostaglandin E2 in rheumatic diseases.

Authors:  B Kollberg; R Nordemar; C Johansson
Journal:  Scand J Gastroenterol       Date:  1981       Impact factor: 2.423

9.  Isolation and characterization of urinary metabolites of arbaprostil in the rat.

Authors:  B A Thornburgh; S R Shaw; A J Wickrema Sinha
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Jan-Mar       Impact factor: 2.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.